Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5085782 | 0.98 | MAPK1 (0.36) | MAPK1ATMCACNA1FCHRM2CHRM1 | |
| Trifluoromethanesulfonic Acid SCHEMBL5090051 | 0.82 | HSD11B1 (0.34) | CYP2D6TSHRALDH1A1 | |
| SCHEMBL20218966 | 0.76 | ATM (0.31) | MAPK1ATMCACNA1FCHRM2CHRM1 | |
| SCHEMBL6902987 | 0.72 | LMNA (0.35) | CACNA1FCHRM2CHRM1ADRA2BCHRM3 | |
| SCHEMBL2268375 | 0.70 | TSHR (0.41) | MAPK1ATMCHRM2ADRA1AHRH1 | |
| SCHEMBL27966762 | 0.70 | TDP1 (0.42) | ATMCHRM2ADRA1ALMNACYP2D6 | |
| SCHEMBL4835275 | 0.70 | MAPK1 (0.33) | MAPK1TSHRALDH1A1ALOX15 | |
| SCHEMBL12273825 | 0.69 | TDP1 (0.35) | MAPK1LMNACYP2D6TSHRALDH1A1 | |
| SCHEMBL8710885 | 0.68 | KCNN4 (0.41) | MAPK1ATMCACNA1FCHRM2CHRM1 | |
| SCHEMBL28114301 | 0.67 | TSHR (0.32) | LMNAKCNN4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138946-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF UPADACITINIB | CURIA SPAIN S A U (ES) | 2026-05-21 | — | — | US | disclosed |
| US-20260062395-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF VILOXAZINE AND OTHER 2-SUBSTITUTED MORPHOLINE DERIVATIVES | CURIA SPAIN S A U (ES) | 2026-03-05 | — | — | US | disclosed |
| US-12552746-B2 | Process and intermediates for the preparation of upadacitinib | CURIA SPAIN, S.A.U. (ES) | 2026-02-17 | — | — | US | disclosed |
| EP-4317141-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF VILOXAZINE AND OTHER 2-SUBSTITUTED MORPHOLINE DERIVATIVES | Curia Spain S.A.U. (ES) | 2024-02-07 | — | — | EP | disclosed |
| US-20230139156-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF UPADACITINIB | CURIA SPAIN, S.A.U. (ES) | 2023-05-04 | — | — | US | disclosed |
| EP-4077276-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF UPADACITINIB | Curia Spain S.A.U. (ES) | 2022-10-26 | — | — | EP | disclosed |
| CN-115151529-A | Process and intermediates for the preparation of Wu Pati ni | 库里亚西班牙公司 | 2022-10-04 | — | — | CN | disclosed |
| US-11312708-B2 | Process and intermediates for the preparation of benzo[b]thiophene compounds | CRYSTAL PHARMA, S.A.U. (ES) | 2022-04-26 | — | — | US | disclosed |
| WO-2021123288-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF UPADACITINIB | CRYSTAL PHARMA, S.A.U. (ES) | 2021-06-24 | — | — | WO | disclosed |
| US-20200172523-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF BENZO[B]THIOPHENE COMPOUNDS | CURIA SPAIN, S.A.U. (ES) | 2020-06-04 | — | — | US | disclosed |
| US-20070051922-A1 | Polymer light-emitting material and polymer light-emitting device | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-03-08 | — | — | US | disclosed |
| EP-0610038-B1 | Preparation of alkylsilyl nitrile | SIVENTO INC (US) | 2001-08-29 | — | — | EP | disclosed |
| CN-1042336-C | Preparation of trialkylsilyl nitrile | HULS AMERICA INC (US) | 1999-03-03 | — | — | CN | disclosed |
| EP-0544757-B1 | NOVEL POLYAMINE CONJUGATED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 1997-10-08 | — | — | EP | disclosed |
| CN-1101913-A | Preparation of trialkylsilyl nitrile | HULS AMERICA INC (US) | 1995-04-26 | — | — | CN | disclosed |
| EP-0610038-A1 | Preparation of alkylsilyl nitrile | HÜLS AMERICA INC. (US) | 1994-08-10 | — | — | EP | disclosed |
| EP-0544757-A4 | NOVEL POLYAMINE CONJUGATED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 1994-07-06 | — | — | EP | disclosed |
| US-5258534-A | Preparation of trialkylsilyl nitrile | HULS AMERICA, INC. (US) | 1993-11-02 | — | — | US | disclosed |
| EP-0544757-A1 | NOVEL POLYAMINE CONJUGATED OLIGONUCLEOTIDES. | ISIS PHARMACEUTICALS INC (US) | 1993-06-09 | — | — | EP | disclosed |
| WO-1992002531-A1 | NOVEL POLYAMINE CONJUGATED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1992-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138946-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF UPADACITINIB | JAK1, JAK3, JAK2 | MAPK1 48/4885ATM 841/4885CACNA1F 3672/4885 |
| US-20200172523-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF BENZO[B]THIOPHENE COMPOUNDS | CYP4X1, CYP2B6, CYP2C19 | MAPK1 949/4885ATM 4530/4885CACNA1F 436/4885 |
| US-20230139156-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF UPADACITINIB | CDK19, CDK11B, CDK9 | MAPK1 166/4885ATM 1359/4885CACNA1F 4754/4885 |
| US-12552746-B2 | Process and intermediates for the preparation of upadacitinib | JAK1, JAK3, MET | MAPK1 37/4885ATM 720/4885CACNA1F 3790/4885 |
| US-11312708-B2 | Process and intermediates for the preparation of benzo[b]thiophene compounds | CYP4X1, CYP2B6, CYP2C19 | MAPK1 949/4885ATM 4530/4885CACNA1F 436/4885 |
| US-20260062395-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF VILOXAZINE AND OTHER 2-SUBSTITUTED MORPHOLINE DERIVATIVES | OGFRL1, SALL4, OGFR | MAPK1 3355/4885ATM 3485/4885CACNA1F 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.